TELA Bio Q2 2024 Earnings Report $2.83 -0.01 (-0.35%) As of 04:00 PM Eastern Earnings HistoryForecast TELA Bio EPS ResultsActual EPS-$0.51Consensus EPS -$0.45Beat/MissMissed by -$0.06One Year Ago EPS-$0.46TELA Bio Revenue ResultsActual Revenue$16.09 millionExpected Revenue$19.00 millionBeat/MissMissed by -$2.91 millionYoY Revenue GrowthN/ATELA Bio Announcement DetailsQuarterQ2 2024Date8/12/2024TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptPress ReleaseTELA Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by BofA Reveals New $1.4 Trillion Opportunity (Ad)Everyone is focusing on AI stocks... Yet little-known "space stocks" are rocketing to record highs with gains of 588% - 3,710%! One new space stock that I call "the next SpaceX" is preparing to IPO on the NASDAQ. Right now, you can grab Pre-IPO shares for less than $4.00. And my estimates suggest the valuation could soar 457% with the IPO. Get urgent details inside this free report...The Next SpaceX Pre-IPO TELA Bio Earnings HeadlinesTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 13, 2024 | globenewswire.comThe past five years for TELA Bio (NASDAQ:TELA) investors has not been profitableDecember 1, 2024 | uk.finance.yahoo.comMy #1 Pre IPO Trade for 2025 – NAME and TICKERSpaceX value has surged to $350 billion... Delivering windfall profits to early investors including Elon Musk and Peter Theil. Right now, you can invest in "the next SpaceX" while its valuation is still below $100 million.January 7, 2025 | Wyatt Investment Research (Ad)TELA Bio Set for Growth with Strategic Enhancements and Financial ImprovementsNovember 23, 2024 | markets.businessinsider.comTELA Bio Set to Unveil Innovations at Piper Sandler’s Premier Healthcare Conference!November 21, 2024 | msn.comTELA Bio to Participate in Piper Sandler’s 36th Annual Healthcare ConferenceNovember 20, 2024 | markets.businessinsider.comSee More TELA Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like TELA Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TELA Bio and other key companies, straight to your email. Email Address About TELA BioTELA Bio (NASDAQ:TELA), a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.View TELA Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles S&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
